Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:CLRBNASDAQ:KTOVNASDAQ:OHRPNASDAQ:PULM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$1.71+0.6%$1.67$0.77▼$14.00$6.93M1.485.12 million shs146,151 shsCLRBCellectar Biosciences$3.06-1.6%$3.65$1.33▼$4.45$98.72M0.921.67 million shs1.04 million shsKTOVPurple Biotech$0.49+8.9%$4.16$2.20▼$14.40$7.71M2.371.18 million shs83,344 shsOHRPOHR Pharmaceutical$0.42$7.37$1.60▼$6.28$1.19M0.84180,228 shs58,425 shsPULMPulmatrix$2.09+3.5%$1.86$1.55▼$3.14$7.63M0.9217,656 shs4,090 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals-10.53%-24.11%0.00%+34.92%-81.62%CLRBCellectar Biosciences-2.51%-6.04%-23.21%-7.44%+115.97%KTOVPurple Biotech+7.69%-16.01%-26.99%-18.63%-74.21%OHRPOHR Pharmaceutical+0.24%+4.73%-59.13%-30.07%+175.70%PULMPulmatrix+0.50%-4.71%+20.96%+6.33%-30.82%Pentagon contract could send this $2 AI stock soaring (Ad)Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals0.7665 of 5 stars0.05.00.00.02.50.80.6CLRBCellectar Biosciences0.8715 of 5 stars3.52.00.00.00.60.00.6KTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix0.9912 of 5 stars3.53.00.00.00.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/ACLRBCellectar Biosciences3.00Buy$20.00553.59% UpsideKTOVPurple BiotechN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/APULMPulmatrix3.00Buy$10.00378.47% UpsideCurrent Analyst RatingsLatest ADIL, PULM, KTOV, CLRB, and OHRP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/ACLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/AKTOVPurple Biotech$1M7.71N/AN/A$5.56 per share0.09OHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/APULMPulmatrix$7.30M1.05N/AN/A$4.93 per share0.42Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)CLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/AOHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/APULMPulmatrix-$14.12M-$3.86N/A∞N/A-193.49%-63.94%-40.88%5/10/2024 (Estimated)Latest ADIL, PULM, KTOV, CLRB, and OHRP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PULMPulmatrixN/A-$0.57-$0.57-$0.57N/A$2.20 million3/27/2024Q4 2023CLRBCellectar Biosciences-$0.59-$0.66-$0.07-$0.92N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A4.904.90CLRBCellectar BiosciencesN/A0.810.81KTOVPurple BiotechN/A2.22N/AOHRPOHR PharmaceuticalN/A3.733.73PULMPulmatrixN/A5.335.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%CLRBCellectar Biosciences16.41%KTOVPurple Biotech30.72%OHRPOHR Pharmaceutical10.70%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%CLRBCellectar Biosciences4.60%KTOVPurple Biotech2.98%OHRPOHR Pharmaceutical12.50%PULMPulmatrix3.61%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals164.05 million3.47 millionNo DataCLRBCellectar Biosciences2032.26 million30.78 millionOptionableKTOVPurple Biotech915.73 millionN/ANot OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionablePULMPulmatrix223.65 million3.52 millionNot OptionableADIL, PULM, KTOV, CLRB, and OHRP HeadlinesSourceHeadlinePulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 24 at 2:22 AMCipla Share Pricebusiness-standard.com - March 29 at 7:49 AMPULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMPulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 28 at 11:46 AMPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Updateprnewswire.com - March 28 at 9:05 AMCipla Ltd CIPLAmorningstar.com - February 15 at 11:00 PMGlobal deaths from fungal disease have doubled in a decade – new studytheconversation.com - January 13 at 7:42 AMFive things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headlinersbizjournals.com - January 10 at 7:51 AMPulmatrix shuts down study, explores salebizjournals.com - January 9 at 3:43 PMPulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Studynasdaq.com - January 8 at 1:11 PMPulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternativesmarketwatch.com - January 8 at 1:11 PMPulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternativesfinance.yahoo.com - January 8 at 1:11 PMStocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata Steelmsn.com - January 8 at 12:42 AMStock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In Focusmsn.com - January 8 at 12:42 AMTrade Setup for Jan 8: IT earnings to be the Nifty 50's focal point this weekcnbctv18.com - January 7 at 9:11 AMPulmatrix Inc PULMmorningstar.com - November 12 at 9:08 AMPulmatrix Down on Q3 Resultsbaystreet.ca - November 9 at 1:38 PMPulmatrix GAAP EPS of -$1.03, revenue of $1.75Mmsn.com - November 9 at 1:38 PMPulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 1:38 PMAspergillosis Treatment Research Report 2023finance.yahoo.com - October 23 at 3:27 PMPulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100markets.businessinsider.com - September 19 at 9:49 AMPulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migrainefinance.yahoo.com - September 19 at 9:49 AMPulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowmsn.com - September 11 at 3:15 PMPulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazolefinance.yahoo.com - August 23 at 6:11 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Cellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.